INTERVENTIONAL ONCOLOGY CORPORATE AND REGIONAL PRESS RELEASES

Please find below a list of our press releases.

5 Oct 2017

BTGplc acquires Roxwood Medical

London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.

27 Sep 2017

Mirada Medical signs three-year software development agreement with BTG

Mirada Medical Ltd, a global medical imaging software company, has signed a three-year master service agreement with BTG plc (LSE: BTG), a global specialist healthcare company. The agreement covers multiple software development projects to support BTG’s portfolio of interventional medicine products.

21 Aug 2017

BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme

BTG plc (LSE: BTG), a global specialist healthcare company, and the Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, have expanded their commitment to the Immuno-Oncology / Interventional Oncology research grant programme, by announcing a second round of funding available to investigators.

10 Jun 2017

New study shows IO Loop™ improves patient follow-up, engagement and satisfaction following treatment with TheraSphere®

Study shows patients treated with TheraSphere® maintain quality of life throughout 90 day post-treatment period

20 Apr 2017

First European Patients Treated With DC Bead LUMI™ Radiopaque Drug-Eluting Beads

BTG plc (LSE: BTG), a global specialist healthcare company, today announced the treatment of the first patients in the EU with DC Bead LUMI™.

7 Mar 2017

BTG announces CE Mark Certification for DC Bead LUMI™, the first commercially available radiopaque drug-eluting bead in the EU

DC Bead LUMI™ provides real-time visible, lasting confirmation of bead location during and post-embolisation of hypervascular tumours in the liver

15 Feb 2017

BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology

BTG plc (LSE: BTG), the global specialist healthcare company, today announced a collaboration with the Society of Interventional Oncology (SIO), a global organization working to nurture and support interventional oncology worldwide, to explore the role of interventional oncology alongside immuno-oncology

5 Dec 2016

PneumRx® Coils included in new global clinical guidelines and given positive recommendation to treat severe emphysema patients in France

BTG plc (LSE: BTG), the global specialist healthcare company, today announces the inclusion of treatment with PneumRx® Coils in guidelines for the management of chronic obstructive pulmonary disease (COPD) published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

5 Dec 2016

Le Canada, premier pays à bénéficier d’une nouvelle option de traitement contre le cancer du foie

Les microsphères radio-opaques à élution médicamenteuse DC Bead LUMIMC offrent aux radiologistes interventionnels du Canada un traitement de nouvelle génération pour les patients atteints d’un cancer du foie

19 Oct 2016

First patient in Malaysia receives TheraSphere™ radioembolisation therapy

BTG plc (LSE: BTG), an international specialist healthcare company, today announced that the first patient in Malaysia was treated with TheraSphere™ – a transarterial radioembolisation (TARE) therapy, which targets primary liver cancer and metastatic colorectal cancer with a powerful dose of radiation while minimising exposure to healthy tissue.

Interventional Oncology